For the last several years, AI governance has focused on a familiar set of questions. What data trained the model? Who is accountable for the output? Can the system explain its decisions? Where is human oversight? What happens when the model is wrong? Those questions still matter, but they are no longer enough.
The next governance frontier is emerging at a much more sensitive boundary: the interface between human intention and machine action.
Brain-computer interfaces are moving from science fiction into real clinical and engineering systems. Neuralink, for example, is actively advancing implantable brain-computer interfaces and continues publishing work on neural decoding, clinical deployment and large-scale neural data. On October 1, 2026, the company published research describing pretraining on 50,000 hours of unlabeled brain data to improve neural decoder performance over time.
That changes the governance conversation. When the data is neural, the machine is no longer merely processing information about a person. It may be processing signals associated with intention itself.
What happens when AI moves closer to the boundary between what we think and what machines do?
This is why the next major governance category will not simply be AI Governance. It will be Neurotechnology Governance, and at its core will be one principle: Human Agency Governance.
AI governance was only the beginning
Traditional AI governance largely assumes a separation between the human and the system. A human gives input. The system processes information and produces an output. The human accepts, rejects or acts on that output.
Brain-computer interfaces can compress that distance dramatically. A neural signal may be decoded. The decoded signal may be interpreted as intention. That intention may trigger an action: a cursor moves, a robotic device responds, a communication system produces language. Eventually, more complex systems may interact with physical environments, digital agents or autonomous machines.
The governance problem is no longer simply “Was the AI output correct?” It becomes “Was the machine interpretation of human intention correct?” Those are very different questions.
The most sensitive data may not be what you type
Governments and enterprises spend enormous effort protecting financial data, medical records, passwords and identities. Neural technology introduces an entirely different category: neural data.
Today, much of this information is highly technical, noisy and context-dependent. But machine learning changes the equation. As models become better at finding patterns in neural signals, the value and sensitivity of neural datasets may increase dramatically. Neuralink’s recent work on tens of thousands of hours of neural recordings illustrates the direction of travel: larger datasets, stronger decoders and systems that can adapt over longer periods without constant recalibration.
That creates questions most organizations are not yet architected to answer.
- Who owns neural data: the individual, the device manufacturer, the healthcare provider or the research institution?
- What about derived data? If an algorithm infers something from a neural signal that the person never explicitly communicated, who owns that inference?
- What if that inference is wrong? What if it is correct?
- What categories of inference should never be made at all?
Consent cannot be a checkbox
Traditional digital consent is already weak. Most people click “Accept” without reading the terms. That model becomes unacceptable when technology is interacting with neural signals. Consent in neurotechnology must become continuous, contextual and capability-aware.
Imagine a brain-computer interface whose capabilities improve through software updates. The device implanted today may not have exactly the same capabilities three years later. The algorithms interpreting neural signals may also evolve, new features may emerge, and new forms of inference may become possible. The original consent given at implantation cannot automatically be assumed to cover every future capability.
We need a concept of Continuing Neural Consent. The user should understand not only what the device does today, but when meaningful capabilities change. Governance must ensure that new capabilities do not silently expand beyond the boundaries originally understood by the individual.
The biggest risk may be interpretation
One of the most dangerous misconceptions about brain-computer interfaces is that the machine simply “reads thoughts.” That description is both technologically simplistic and governance-dangerous. These systems interpret signals, and interpretation introduces uncertainty.
Suppose a neural decoder predicts intention A when the individual intended B. Who is responsible? The model developer? The device company? The clinician? The user? The organization deploying the downstream system? Now imagine that decoded intention triggers an autonomous system. The problem becomes much more significant. The future governance chain may look something like this:
Neural signal → interpretation → AI decision → machine action
Every transition introduces potential error. Every transition requires accountability. Every transition needs evidence. That is not merely a medical-device issue. It is an architecture issue.
Human-in-the-loop is not enough
AI governance has relied heavily on the phrase “human in the loop.” Neurotechnology complicates that model. What if the human is not simply supervising the loop, but is becoming part of the interface itself? We may need a stronger principle: Human Sovereignty Over the Loop.
The individual must retain meaningful control over:
- what signals are captured,
- how those signals are interpreted,
- what downstream systems may act upon them,
- what data is stored,
- what derived insights are created,
- and when the system must stop.
This is larger than human oversight. It is about cognitive sovereignty.
Seven domains of Neurotechnology Governance
Organizations working in this space will eventually need a governance architecture that extends beyond clinical safety and cybersecurity. I propose seven domains.
- Human Agency. The individual must remain the authoritative source of intent. Technology may assist interpretation, but it should not quietly redefine human intention.
- Neural Data Rights. Neural information deserves explicit governance covering collection, retention, access, portability, deletion and derived inference.
- Continuing Consent. Consent must evolve when device capabilities, algorithms, use cases or data practices materially change.
- Algorithmic Interpretation. Organizations must govern how neural signals are translated into meaning. Accuracy alone is insufficient; uncertainty, confidence and failure modes matter.
- Device and Model Safety. Hardware safety and AI-model safety cannot be treated as separate worlds. The interface between the two must be governed.
- Decision Rights and Accountability. Every system must answer who has authority to approve, override, stop and investigate a machine action.
- Cognitive Sovereignty. Certain areas of human thought, intention and identity may require stronger protection than ordinary personal data. That conversation should begin now, not after the market is mature.
Governance must be designed into neurotechnology
The encouraging sign is that the neurotechnology community is already starting to treat trust, standards and ethics as engineering questions rather than abstract philosophy.
The upcoming IEEE Brain Discovery & Neurotechnology Workshop, taking place November 11–13, 2026 in Washington, D.C., includes an entire panel titled “Engineering Trust: Implementing NeuroTech Standards at the Design Level.” The event also includes discussions on ethical implications, standards, clinical challenges, data privacy and user-centered design. Neuralink’s Head of Clinical, Erika Ross Ellison, is scheduled to deliver a plenary address on November 13.
That matters, because governance in this field cannot arrive after deployment. It must be embedded in the architecture.
Neuralink is becoming more than a technology story
The public often sees Neuralink primarily through the lens of engineering innovation. But its organizational evolution tells another story. Neuralink currently lists roles in privacy and compliance, regulatory engineering, quality systems, software design controls, security and clinical operations alongside its hardware, software and robotics positions.
That is significant. It signals that the challenge of scaling neurotechnology is not only technical. It is organizational, legal, regulatory, ethical and architectural. The organizations that succeed in neurotechnology will not be those that merely build the most powerful interface. They will be those that can answer: Why should humans trust it?
The enterprise architecture problem nobody is discussing
Eventually, brain-computer interfaces will interact with systems beyond the medical environment: communication platforms, work environments, robotics, accessibility systems, AI agents, enterprise software, physical devices and perhaps even autonomous infrastructure. At that point, the question becomes where does the BCI end and the enterprise begin?
This is where Enterprise Architecture becomes relevant. Organizations will need to map:
- neural data flows,
- authorization boundaries,
- model dependencies,
- decision rights,
- audit trails,
- third-party systems,
- human override mechanisms,
- regulatory obligations,
- and accountability chains.
A diagram of applications will not be enough. We will need an architecture of human-machine authority.
The question is not whether neurotechnology should advance
It should. The potential to restore communication, independence and mobility for people with neurological conditions is extraordinary. The mistake would be framing governance as something that slows innovation. Good governance does the opposite: it creates the conditions under which powerful technologies can scale without destroying trust.
The goal is not to stop brain-computer interfaces. The goal is to ensure that as the interface becomes more powerful, the human does not become less sovereign.
The next governance question
The Intelligence Age began with machines learning from human data. Then machines started generating content. Then they began making recommendations. Then decisions. Then actions. Now we are approaching a different boundary: machines that interact directly with signals generated by the human nervous system. That boundary deserves a governance architecture of its own.
Because the ultimate question is no longer only “Can we trust artificial intelligence?” It is:
Can we preserve human agency when intelligence becomes part of the interface itself?
That is the conversation we should start before the technology forces us to have it. And that is why the next frontier of AI governance is not artificial intelligence. It is human intention.
Proposed initiative: ARCHAI Neurotechnology Governance Framework. Editorial series: The 100 Conversations Shaping the Intelligence Age™.
